Clinical Trial Update: Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for MGTA-456 in high-risk hematologic malignancies; results were posted in 2024 and the study is currently active but not recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Burkitt Lymphoma
• Chronic Myeloid Leukemia
• Hodgkin Lymphoma
• Large Cell Lymphoma
• Mantle Cell Lymphoma
• Myelodysplastic Syndromes

Drugs mentioned

• MGTA-456

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-01-30